SUS Incorporates Novel Drug to Combat Aggressive Breast cancer
Brasília,Brazil – In a landmark move for cancer care in Brazil,the Unified Health System (SUS) has begun offering Trastuzumab Entansine,a groundbreaking medicine for the treatment of HER2-positive breast cancer.The frist shipment of the drug, known for its efficacy against a particularly aggressive form of the disease, was received by the Ministry of Health this Monday.
the initial delivery comprises approximately 12,000 units of Trastuzumab Entansine, available in 100mg and 160mg dosages. The Ministry of Health has secured a total of four batches of the medication, wiht subsequent deliveries planned for December 2025, March 2026, and June 2026. These phased deliveries are designed to meet 100% of current patient demand.
This vital treatment will directly benefit an estimated 1,144 patients throughout the current year. Trastuzumab Entansine is specifically indicated for women experiencing persistent symptoms despite undergoing initial chemotherapy, and who have been diagnosed with HER2-positive stage III breast cancer.
The Brazilian government successfully negotiated the purchase of Trastuzumab Entansine at a price 50% below prevailing market rates, representing a significant cost savings for the SUS.The total investment in securing this crucial medication amounted to R$159 million (approximately [insert current USD equivalent]).
Expanding Access to Advanced Breast Cancer Treatments
Beyond Trastuzumab Entansine, the federal government is also accelerating the provision of cyclin inhibitors. These medications are designed for the treatment of advanced or metastatic breast cancer,encompassing both hormone receptor-positive and HER2-negative subtypes.
An ordinance authorizing the decentralized procurement of these cyclin inhibitors is slated for publication later this month, coinciding with Pink October – the annual international campaign dedicated to raising awareness about breast cancer prevention and early detection. This timing underscores the government’s commitment to proactive breast health initiatives.
This expansion of treatment options within the SUS represents a major step forward in providing comprehensive and cutting-edge care for Brazilian women battling breast cancer.
